Regulatory approval

Published by the European Medicines Agency.

The European Medicines Agency (EMA) has authorized imatinib as a monotherapy treatment for adult patients with relapased or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).

This is written in the approval document as:

Glivec is indicated for the treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy.

Citation

Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib